Trial Profile

Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Loncastuximab tesirine (Primary) ; Melphalan (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions

11 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.
04 Jan 2023 Planned initiation date changed from 7 Dec 2022 to 1 Apr 2023.
07 Nov 2022 Planned initiation date changed from 3 Nov 2022 to 7 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com